Jieru Meng

774 total citations
13 papers, 554 citations indexed

About

Jieru Meng is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Jieru Meng has authored 13 papers receiving a total of 554 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Pathology and Forensic Medicine and 5 papers in Oncology. Recurrent topics in Jieru Meng's work include Cancer Mechanisms and Therapy (6 papers), Peptidase Inhibition and Analysis (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Jieru Meng is often cited by papers focused on Cancer Mechanisms and Therapy (6 papers), Peptidase Inhibition and Analysis (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Jieru Meng collaborates with scholars based in United States, China and United Kingdom. Jieru Meng's co-authors include Bingliang Fang, John D. Minna, Bingbing Dai, Jack A. Roth, William G. Bornmann, Lin Ji, Michael Peyton, Paul D. Smith, Christine M. Chresta and Jack A. Roth and has published in prestigious journals such as PLoS ONE, Cancer Research and Clinical Cancer Research.

In The Last Decade

Jieru Meng

13 papers receiving 546 citations

Peers

Jieru Meng
Jing-Yuan Liu United States
David Paladino United States
Chris J. Novotny United States
Enrica Favini Italy
Ruth Ruddle United Kingdom
Jennifer M. Shipman United States
Long Shan Li United States
Sina Haftchenary Canada
Steffanie L. Furtek United States
Marion Peyressatre France
Jing-Yuan Liu United States
Jieru Meng
Citations per year, relative to Jieru Meng Jieru Meng (= 1×) peers Jing-Yuan Liu

Countries citing papers authored by Jieru Meng

Since Specialization
Citations

This map shows the geographic impact of Jieru Meng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jieru Meng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jieru Meng more than expected).

Fields of papers citing papers by Jieru Meng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jieru Meng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jieru Meng. The network helps show where Jieru Meng may publish in the future.

Co-authorship network of co-authors of Jieru Meng

This figure shows the co-authorship network connecting the top 25 collaborators of Jieru Meng. A scholar is included among the top collaborators of Jieru Meng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jieru Meng. Jieru Meng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Meng, Jieru & Changbao Li. (2017). A Study on Self-Translation of Eileen Chang’s Little Finger Up From Perspective of Translator’s Subjectivity. Cross-cultural communication. 13(1). 10–19. 1 indexed citations
2.
Wang, Ke, Peiguo Liu, Hanqing Liu, & Jieru Meng. (2017). A miniaturized, self-actuated, energy selective spatial filter. 1689–1692. 2 indexed citations
3.
Li, Weina, Qiang Hao, Liqing He, et al.. (2014). Recombinant IFN-α2a-NGR exhibits higher inhibitory function on tumor neovessels formation compared with IFN-α2a in vivo and in vitro. Cytotechnology. 67(6). 1039–1050. 3 indexed citations
4.
Dai, Bingbing, Suk-Young Yoo, Geoffrey Bartholomeusz, et al.. (2013). KEAP1-Dependent Synthetic Lethality Induced by AKT and TXNRD1 Inhibitors in Lung Cancer. Cancer Research. 73(17). 5532–5543. 55 indexed citations
5.
Lu, Haibo, Li Wang, Wen Gao, et al.. (2013). IGFBP2/FAK Pathway Is Causally Associated with Dasatinib Resistance in Non–Small Cell Lung Cancer Cells. Molecular Cancer Therapeutics. 12(12). 2864–2873. 52 indexed citations
6.
Meng, Jieru, Mourad Majidi, Bingliang Fang, et al.. (2013). The Tumor Suppressor Gene TUSC2 (FUS1) Sensitizes NSCLC to the AKT Inhibitor MK2206 in LKB1-dependent Manner. PLoS ONE. 8(10). e77067–e77067. 16 indexed citations
7.
Li, Long Shan, Erik A. Bey, Ying Dong, et al.. (2011). Modulating Endogenous NQO1 Levels Identifies Key Regulatory Mechanisms of Action of β-Lapachone for Pancreatic Cancer Therapy. Clinical Cancer Research. 17(2). 275–285. 94 indexed citations
8.
Dai, Bingbing, Jieru Meng, Michael Peyton, et al.. (2011). STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA miR-17. Cancer Research. 71(10). 3658–3668. 80 indexed citations
9.
Meng, Jieru, Bingliang Fang, Yong Liao, et al.. (2010). Apoptosis Induction by MEK Inhibition in Human Lung Cancer Cells Is Mediated by Bim. PLoS ONE. 5(9). e13026–e13026. 54 indexed citations
10.
Meng, Jieru, Bingbing Dai, Bingliang Fang, et al.. (2010). Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo. PLoS ONE. 5(11). e14124–e14124. 127 indexed citations
11.
Meng, Jieru, Bingbing Dai, Wei Guo, et al.. (2009). High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Cancer Biology & Therapy. 8(21). 2073–2080. 51 indexed citations
12.
Meng, Jieru, Zhen Yan, Yongjie Wu, et al.. (2007). Preclinical safety evaluation of IFNα2a-NGR. Regulatory Toxicology and Pharmacology. 50(3). 294–302. 7 indexed citations
13.
Meng, Jieru, Nan Ma, Zhen Yan, Wei Han, & Yingqi Zhang. (2006). NGR Enhanced the Anti-Angiogenic Activity of tum-5. The Journal of Biochemistry. 140(2). 299–304. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jing-Yuan Liu Breakdown of academic impact, for papers by David Paladino Breakdown of academic impact, for papers by Chris J. Novotny Breakdown of academic impact, for papers by Enrica Favini Breakdown of academic impact, for papers by Ruth Ruddle Breakdown of academic impact, for papers by Jennifer M. Shipman Breakdown of academic impact, for papers by Long Shan Li Breakdown of academic impact, for papers by Sina Haftchenary Breakdown of academic impact, for papers by Steffanie L. Furtek Breakdown of academic impact, for papers by Marion Peyressatre
Rankless by CCL
2026